CoChat
Sign Up
Cited by 381Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Dementia with Lewy bodies: an update and outlook

Open access
Outeiro, Tiago Fleming, Koss, David J., Erskine, Daniel, Walker, Lauren, Kurzawa-Akanbi, Marzena, Burn, David, Donaghy, Paul, Morris, Christopher +4 more·2019·Molecular Neurodegeneration
DOI 10.1186/s13024-019-0306-8PMC PMC6341685
Open this paper in CoChat — free accountOpen PDF

Abstract

Dementia with Lewy bodies (DLB) is an age-associated neurodegenerative disorder producing progressive cognitive decline that interferes with normal life and daily activities. Neuropathologically, DLB is characterised by the accumulation of aggregated α-synuclein protein in Lewy bodies and Lewy neurites, similar to Parkinson's disease (PD). Extrapyramidal motor features characteristic of PD, are common in DLB patients, but are not essential for the clinical diagnosis of DLB. Since many PD patients develop dementia as disease progresses, there has been controversy about the separation of DLB from PD dementia (PDD) and consensus reports have put forward guidelines to assist clinicians in the identification and management of both syndromes. Here, we present basic concepts and definitions, based on our current understanding, that should guide the community to address open questions that will, hopefully, lead us towards improved diagnosis and novel therapeutic strategies for DLB and other synucleinopathies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13024-019-0306-8

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Recent genetic studies demonstrated a robust association between the APOE4 allele and risk of dementia with Lewy bodies.

    “Additionally, recent genetic studies have also demonstrated a robust association between the APOE4 allele and risk of DLB (6, 12), the second leading cause of dementia in the elderly.”

    From <i>APOE3</i> -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia (2021) · cites this paper as [12]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 199

  1. [1]Van Den Eeden SK Tanner CM Bernstein AL Fross RD Leimpeter A Bloch DA Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity American journal of epidemiology. 2003 157 11 1015 1022 10.1093/aje/kwg068 12777365 · DOI
  2. [2]Bostrom F Jonsson L Minthon L Londos E Patients with Lewy body dementia use more resources than those with Alzheimer's disease International journal of geriatric psychiatry. 2007 22 8 713 719 10.1002/gps.1738 17195278 · DOI
  3. [3]Spillantini MG Schmidt ML Lee VM Trojanowski JQ Jakes R Goedert M Alpha-synuclein in Lewy bodies Nature. 1997 388 6645 839 840 10.1038/42166 9278044 · DOI · Paper page
  4. [4]Jellinger KA Neuropathological spectrum of synucleinopathies Movement disorders: official journal of the Movement Disorder Society. 2003 18 Suppl 6 S2 12 10.1002/mds.10557 14502650 · DOI
  5. [5]Polymeropoulos MH Lavedan C Leroy E Ide SE Dehejia A Dutra A Mutation in the alpha-synuclein gene identified in families with Parkinson's disease Science. 1997 276 5321 2045 2047 10.1126/science.276.5321.2045 9197268 · DOI · Paper page
  6. [6]Jellinger KA Lantos PL Papp-Lantos inclusions and the pathogenesis of multiple system atrophy: an update Acta neuropathologica. 2010 119 6 657 667 10.1007/s00401-010-0672-3 20309568 · DOI
  7. [7]Kosaka K Lewy bodies in cerebral cortex, report of three cases Acta neuropathologica. 1978 42 2 127 134 10.1007/BF00690978 654884 · DOI
  8. [8]McKeith IG Galasko D Kosaka K Perry EK Dickson DW Hansen LA Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop Neurology. 1996 47 5 1113 1124 10.1212/WNL.47.5.1113 8909416 · DOI · Paper page
  9. [9]McKeith IG Perry EK Perry RH Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies Neurology. 1999 53 5 902 905 10.1212/WNL.53.5.902 10496243 · DOI
  10. [11]McKeith IG Boeve BF Dickson DW Halliday G Taylor JP Weintraub D Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium Neurology. 2017 89 1 88 100 10.1212/WNL.0000000000004058 28592453 PMC5496518 · DOI · Paper page
  11. [12]Vann Jones SA O'Brien JT The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies Psychol Med. 2014 44 4 673 683 10.1017/S0033291713000494 23521899 · DOI
  12. [13]Schrag A Ben-Shlomo Y Quinn N How valid is the clinical diagnosis of Parkinson's disease in the community? Journal of neurology, neurosurgery, and psychiatry. 2002 73 5 529 534 10.1136/jnnp.73.5.529 12397145 PMC1738115 · DOI
  13. [14]Jellinger KA How valid is the clinical diagnosis of Parkinson's disease in the community? Journal of neurology, neurosurgery, and psychiatry. 2003 74 7 1005 1006 10.1136/jnnp.74.7.1005 12810810 PMC1738558 · DOI
  14. [15]Kosaka K Yoshimura M Ikeda K Budka H Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree--a new disease? Clinical neuropathology. 1984 3 5 185 192 6094067
  15. [16]Dickson DW Davies P Mayeux R Crystal H Horoupian DS Thompson A Diffuse Lewy body disease. Neuropathological and biochemical studies of six patients Acta neuropathologica. 1987 75 1 8 15 10.1007/BF00686786 3434218 · DOI
  16. [17]Lennox G Lowe JS Godwin-Austen RB Landon M Mayer RJ Diffuse Lewy body disease: an important differential diagnosis in dementia with extrapyramidal features Progress in clinical and biological research. 1989 317 121 130 2602409
  17. [18]Gibb WR Esiri MM Lees AJ Clinical and pathological features of diffuse cortical Lewy body disease (Lewy body dementia) Brain: a journal of neurology. 1987 110 Pt 5 1131 1153 10.1093/brain/110.5.1131 2823957 · DOI
  18. [20]Hansen L Salmon D Galasko D Masliah E Katzman R DeTeresa R The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity Neurology. 1990 40 1 1 8 10.1212/WNL.40.1.1 2153271 · DOI · Paper page
  19. [21]Forstl H Burns A Luthert P Cairns N Levy R The Lewy-body variant of Alzheimer's disease. Clinical and pathological findings The British journal of psychiatry: the journal of mental science. 1993 162 385 392 10.1192/bjp.162.3.385 8453435 · DOI
  20. [22]Perry RH Irving D Blessed G Fairbairn A Perry EK Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly Journal of the neurological sciences. 1990 95 2 119 139 10.1016/0022-510X(90)90236-G 2157823 · DOI
  21. [23]Mckeith I Dementia with Lewy bodies: A Clinical Overview. In: Ames D, O'Brien, Burns, A, editor. Dementia 2017 Boca Raton CRC Press
  22. [24]Tiraboschi P Attems J Thomas A Brown A Jaros E Lett DJ Clinicians' ability to diagnose dementia with Lewy bodies is not affected by beta-amyloid load Neurology. 2015 84 5 496 499 10.1212/WNL.0000000000001204 25552579 PMC4336072 · DOI
  23. [26]Toledo JB Cairns NJ Da X Chen K Carter D Fleisher A Clinical and multimodal biomarker correlates of ADNI neuropathological findings Acta neuropathologica communications. 2013 1 65 10.1186/2051-5960-1-65 24252435 PMC3893373 · DOI
  24. [27]Thomas AJ Mahin-Babaei F Saidi M Lett D Taylor JP Walker L Improving the identification of dementia with Lewy bodies in the context of an Alzheimer's-type dementia Alzheimer's research & therapy. 2018 10 1 27 10.1186/s13195-018-0356-0 PMC5831205 29490691 · DOI
  25. [28]Kane JPM Surendranathan A Bentley A Barker SAH Taylor JP Thomas AJ Clinical prevalence of Lewy body dementia Alzheimer's research & therapy. 2018 10 1 19 10.1186/s13195-018-0350-6 PMC5815202 29448953 · DOI
  26. [29]Galvin JE Improving the clinical detection of lewy body dementia with the lewy body composite risk score Alzheimer's & dementia (Amsterdam, Netherlands) 2015 1 3 316 324 PMC4576496 26405688
  27. [30]Thomas AJ Taylor JP McKeith I Bamford C Burn D Allan L Development of assessment toolkits for improving the diagnosis of the Lewy body dementias: feasibility study within the DIAMOND Lewy study International journal of geriatric psychiatry. 2017 32 12 1280 1304 10.1002/gps.4609 27928840 PMC5724510 · DOI
  28. [31]Thomas AJ Taylor JP McKeith I Bamford C Burn D Allan L Revision of assessment toolkits for improving the diagnosis of Lewy body dementia: The DIAMOND Lewy study International journal of geriatric psychiatry. 2018 33 10 1293 1304 10.1002/gps.4948 30091150 PMC6221009 · DOI
  29. [32]Rizzo G Arcuti S Copetti M Alessandria M Savica R Fontana A Accuracy of clinical diagnosis of dementia with Lewy bodies: a systematic review and meta-analysis Journal of neurology, neurosurgery, and psychiatry. 2018 89 4 358 366 10.1136/jnnp-2017-316844 29030419 · DOI
  30. [33]Donaghy PC Taylor JP O'Brien JT Barnett N Olsen K Colloby SJ Neuropsychiatric symptoms and cognitive profile in mild cognitive impairment with Lewy bodies Psychol Med. 2018 48 14 2384 2390 10.1017/S0033291717003956 29362011 · DOI
  31. [34]Boeve BF Dickson DW Duda JE Ferman TJ Galasko DR Galvin JE Arguing against the proposed definition changes of PD Movement disorders: official journal of the Movement Disorder Society. 2016 31 11 1619 1622 10.1002/mds.26721 27492190 PMC5168716 · DOI
  32. [36]Emanuele M Esposito A Camerini S Antonucci F Ferrara S Seghezza S Exogenous Alpha-Synuclein Alters Pre- and Post-Synaptic Activity by Fragmenting Lipid Rafts EBioMedicine. 2016 7 191 204 10.1016/j.ebiom.2016.03.038 27322472 PMC4909369 · DOI
  33. [37]Jellinger KA Korczyn AD Are dementia with Lewy bodies and Parkinson's disease dementia the same disease? BMC medicine. 2018 16 1 34 10.1186/s12916-018-1016-8 29510692 PMC5840831 · DOI
  34. [38]McKeith I O'Brien J Walker Z Tatsch K Booij J Darcourt J Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study Lancet neurology. 2007 6 4 305 313 10.1016/S1474-4422(07)70057-1 17362834 · DOI · Paper page
  35. [40]Zaccai J Brayne C McKeith I Matthews F Ince PG Patterns and stages of alpha-synucleinopathy: Relevance in a population-based cohort Neurology. 2008 70 13 1042 1048 10.1212/01.wnl.0000306697.48738.b6 18362284 · DOI
  36. [41]Beach TG Adler CH Lue L Sue LI Bachalakuri J Henry-Watson J Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction Acta neuropathologica. 2009 117 6 613 634 10.1007/s00401-009-0538-8 19399512 PMC2757320 · DOI · Paper page
  37. [42]Benamer TS Patterson J Grosset DG Booij J de Bruin K van Royen E Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group Movement disorders: official journal of the Movement Disorder Society. 2000 15 3 503 510 10.1002/1531-8257(200005)15:3<503::AID-MDS1013>3.0.CO;2-V 10830416 · DOI
  38. [43]Lloyd JJ Petrides G Donaghy PC Colloby SJ Attems J O'Brien JT A new visual rating scale for Ioflupane imaging in Lewy body disease NeuroImage: Clinical. 2018 20 823 829 10.1016/j.nicl.2018.09.012 30268991 PMC6169248 · DOI
  39. [44]Booij J Dubroff J Pryma D Yu J Agarwal R Lakhani P Diagnostic Performance of the Visual Reading of (123)I-Ioflupane SPECT Images With or Without Quantification in Patients With Movement Disorders or Dementia Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2017 58 11 1821 1826 10.2967/jnumed.116.189266 28473597 · DOI
  40. [45]Nicastro N Garibotto V Allali G Assal F Burkhard PR Added Value of Combined Semi-Quantitative and Visual [123I]FP-CIT SPECT Analyses for the Diagnosis of Dementia With Lewy Bodies Clinical nuclear medicine. 2017 42 2 e96 e102 10.1097/RLU.0000000000001477 27941373 · DOI
  41. [46]Morgan S Kemp P Booij J Costa DC Padayachee S Lee L Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT Journal of neurology, neurosurgery, and psychiatry. 2012 83 11 1063 1070 10.1136/jnnp-2012-302577 22869921 · DOI
  42. [47]Kashihara K Ohno M Kawada S Okumura Y Reduced cardiac uptake and enhanced washout of 123I-MIBG in pure autonomic failure occurs conjointly with Parkinson's disease and dementia with Lewy bodies Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2006 47 7 1099 1101 16818943
  43. [48]Tiraboschi P Corso A Guerra UP Nobili F Piccardo A Calcagni ML (123) I-2beta-carbomethoxy-3beta-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography and (123) I-metaiodobenzylguanidine myocardial scintigraphy in differentiating dementia with lewy bodies from other dementias: A comparative study Annals of neurology. 2016 80 3 368 378 10.1002/ana.24717 27398636 · DOI
  44. [49]Yoshita M Taki J Yokoyama K Noguchi-Shinohara M Matsumoto Y Nakajima K Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD Neurology. 2006 66 12 1850 1854 10.1212/01.wnl.0000219640.59984.a7 16801649 · DOI
  45. [50]Hanyu H Shimizu S Hirao K Kanetaka H Iwamoto T Chikamori T Comparative value of brain perfusion SPECT and [(123)I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer's disease European journal of nuclear medicine and molecular imaging. 2006 33 3 248 253 10.1007/s00259-005-1921-x 16328506 · DOI
  46. [51]Yoshita M Arai H Arai H Arai T Asada T Fujishiro H Diagnostic accuracy of 123I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies: a multicenter study PloS one. 2015 10 3 e0120540 10.1371/journal.pone.0120540 25793585 PMC4368705 · DOI
  47. [52]Komatsu J, Samuraki M, Nakajima K, Arai H, Arai H, Arai T, et al. (123)I-MIBG myocardial scintigraphy for the diagnosis of DLB: a multicentre 3-year follow-up study. Journal of neurology, neurosurgery, and psychiatry. 2018. 29853532
  48. [53]Flotats A Carrio I Agostini D Le Guludec D Marcassa C Schafers M Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology European journal of nuclear medicine and molecular imaging. 2010 37 9 1802 1812 10.1007/s00259-010-1491-4 20577740 · DOI
  49. [55]Ferman TJ Boeve BF Smith GE Lin SC Silber MH Pedraza O Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies Neurology. 2011 77 9 875 882 10.1212/WNL.0b013e31822c9148 21849645 PMC3162640 · DOI
  50. [57]Nedelska Z Ferman TJ Boeve BF Przybelski SA Lesnick TG Murray ME Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies Neurobiology of aging. 2015 36 1 452 461 10.1016/j.neurobiolaging.2014.07.005 25128280 PMC4268128 · DOI · Paper page
  51. [58]O'Brien JT Firbank MJ Davison C Barnett N Bamford C Donaldson C 18F-FDG PET and Perfusion SPECT in the Diagnosis of Alzheimer and Lewy Body Dementias Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2014 55 12 1959 1965 10.2967/jnumed.114.143347 25453043 · DOI · Paper page
  52. [59]Bonanni L Thomas A Tiraboschi P Perfetti B Varanese S Onofrj M EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up Brain: a journal of neurology. 2008 131 Pt 3 690 705 10.1093/brain/awm322 18202105 · DOI
  53. [60]Bonanni L Franciotti R Nobili F Kramberger MG Taylor JP Garcia-Ptacek S EEG Markers of Dementia with Lewy Bodies: A Multicenter Cohort Study Journal of Alzheimer's disease: JAD. 2016 54 4 1649 1657 10.3233/JAD-160435 27589528 · DOI
  54. [61]Stylianou M Murphy N Peraza LR Graziadio S Cromarty R Killen A Quantitative electroencephalography as a marker of cognitive fluctuations in dementia with Lewy bodies and an aid to differential diagnosis Clinical neurophysiology: official journal of the International Federation of Clinical Neurophysiology. 2018 129 6 1209 1220 10.1016/j.clinph.2018.03.013 29656189 PMC5954167 · DOI · Paper page
  55. [62]Briel RC McKeith IG Barker WA Hewitt Y Perry RH Ince PG EEG findings in dementia with Lewy bodies and Alzheimer's disease Journal of neurology, neurosurgery, and psychiatry. 1999 66 3 401 403 10.1136/jnnp.66.3.401 10084544 PMC1736269 · DOI
  56. [63]Babiloni C Del Percio C Lizio R Noce G Cordone S Lopez S Abnormalities of cortical neural synchronization mechanisms in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study Neurobiology of aging. 2017 55 143 158 10.1016/j.neurobiolaging.2017.03.030 28454845 · DOI
  57. [64]Peraza LR Cromarty R Kobeleva X Firbank MJ Killen A Graziadio S Electroencephalographic derived network differences in Lewy body dementia compared to Alzheimer's disease patients Scientific reports. 2018 8 1 4637 10.1038/s41598-018-22984-5 29545639 PMC5854590 · DOI
  58. [65]Bonanni L Perfetti B Bifolchetti S Taylor JP Franciotti R Parnetti L Quantitative electroencephalogram utility in predicting conversion of mild cognitive impairment to dementia with Lewy bodies Neurobiology of aging. 2015 36 1 434 445 10.1016/j.neurobiolaging.2014.07.009 25129239 PMC4270449 · DOI
  59. [66]Babiloni C Del Percio C Lizio R Noce G Lopez S Soricelli A Abnormalities of resting-state functional cortical connectivity in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study Neurobiology of aging. 2018 65 18 40 10.1016/j.neurobiolaging.2017.12.023 29407464 · DOI
  60. [67]Mukaetova-Ladinska EB Monteith R Perry EK Cerebrospinal fluid biomarkers for dementia with lewy bodies International journal of Alzheimer's disease. 2010 2010 536538 10.4061/2010/536538 21048932 PMC2965495 · DOI
  61. [68]Mollenhauer B Schlossmacher MG CSF synuclein: adding to the biomarker footprint of dementia with Lewy bodies Journal of neurology, neurosurgery, and psychiatry. 2010 81 6 590 591 10.1136/jnnp.2010.206391 20522867 · DOI
  62. [69]Irwin DJ Xie SX Coughlin D Nevler N Akhtar RS McMillan CT CSF tau and beta-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders Neurology. 2018 90 12 e1038 e1e46 10.1212/WNL.0000000000005166 29467305 PMC5874449 · DOI
  63. [70]Kotzbauer PT Tu Z Mach RH Current status of the development of PET radiotracers for imaging alpha synuclein aggregates in Lewy bodies and Lewy neurites Clinical and Translational Imaging. 2017 5 1 3 14 10.1007/s40336-016-0217-4 · DOI
  64. [71]Donadio V Incensi A Rizzo G Capellari S Pantieri R Stanzani Maserati M A new potential biomarker for dementia with Lewy bodies: Skin nerve alpha-synuclein deposits Neurology. 2017 89 4 318 326 10.1212/WNL.0000000000004146 28667178 · DOI
  65. [72]Stokholm MG Danielsen EH Hamilton-Dutoit SJ Borghammer P Pathological alpha-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients Annals of neurology. 2016 79 6 940 949 10.1002/ana.24648 27015771 · DOI · Paper page
  66. [73]Nervi A Reitz C Tang MX Santana V Piriz A Reyes D Familial aggregation of dementia with Lewy bodies Arch Neurol. 2011 68 1 90 93 10.1001/archneurol.2010.319 21220678 PMC3268781 · DOI
  67. [74]Woodruff BK Graff-Radford NR Ferman TJ Dickson DW DeLucia MW Crook JE Family history of dementia is a risk factor for Lewy body disease Neurology. 2006 66 12 1949 1950 10.1212/01.wnl.0000219812.20616.b3 16801670 · DOI
  68. [75]Nussbaum RL Polymeropoulos MH Genetics of Parkinson's disease Hum Mol Genet. 1997 6 10 1687 1691 10.1093/hmg/6.10.1687 9300660 · DOI
  69. [76]Golbe LI Di Iorio G Sanges G Lazzarini AM La Sala S Bonavita V Clinical genetic analysis of Parkinson's disease in the Contursi kindred Annals of neurology. 1996 40 5 767 775 10.1002/ana.410400513 8957018 · DOI
  70. [77]Yamaguchi K Cochran EJ Murrell JR Polymeropoulos MH Shannon KM Crowther RA Abundant neuritic inclusions and microvacuolar changes in a case of diffuse Lewy body disease with the A53T mutation in the alpha-synuclein gene Acta neuropathologica. 2005 110 3 298 305 10.1007/s00401-005-1042-4 15981014 · DOI
  71. [78]Zarranz JJ Alegre J Gomez-Esteban JC Lezcano E Ros R Ampuero I The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia Annals of neurology. 2004 55 2 164 173 10.1002/ana.10795 14755719 · DOI · Paper page
  72. [79]Chen CY Bonham AC Schelegle ES Gershwin LJ Plopper CG Joad JP Extended allergen exposure in asthmatic monkeys induces neuroplasticity in nucleus tractus solitarius The Journal of allergy and clinical immunology. 2001 108 4 557 562 10.1067/mai.2001.118132 11590381 · DOI
  73. [80]Singleton AB Farrer M Johnson J Singleton A Hague S Kachergus J alpha-Synuclein locus triplication causes Parkinson's disease Science 2003 302 5646 841 10.1126/science.1090278 14593171 · DOI · Paper page
  74. [81]Muenter MD Forno LS Hornykiewicz O Kish SJ Maraganore DM Caselli RJ Hereditary form of parkinsonism--dementia Annals of neurology. 1998 43 6 768 781 10.1002/ana.410430612 9629847 · DOI
  75. [82]Uchiyama T Ikeuchi T Ouchi Y Sakamoto M Kasuga K Shiga A Prominent psychiatric symptoms and glucose hypometabolism in a family with a SNCA duplication Neurology. 2008 71 16 1289 1291 10.1212/01.wnl.0000327607.28928.e6 18852445 · DOI
  76. [83]Kara E Kiely AP Proukakis C Giffin N Love S Hehir J A 6.4 Mb duplication of the alpha-synuclein locus causing frontotemporal dementia and Parkinsonism: phenotype-genotype correlations JAMA Neurol. 2014 71 9 1162 1171 10.1001/jamaneurol.2014.994 25003242 PMC4362700 · DOI
  77. [84]Kojovic M Sheerin UM Rubio-Agusti I Saha A Bras J Gibbons V Young-onset parkinsonism due to homozygous duplication of alpha-synuclein in a consanguineous family Movement disorders: official journal of the Movement Disorder Society. 2012 27 14 1827 1829 10.1002/mds.25199 23283657 · DOI
  78. [85]Ikeuchi T Kakita A Shiga A Kasuga K Kaneko H Tan CF Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia Arch Neurol. 2008 65 4 514 519 10.1001/archneur.65.4.514 18413475 · DOI
  79. [86]Wakabayashi K Hayashi S Ishikawa A Hayashi T Okuizumi K Tanaka H Autosomal dominant diffuse Lewy body disease Acta neuropathologica. 1998 96 2 207 210 10.1007/s004010050883 9705138 · DOI
  80. [87]Ishikawa A Takahashi H Tanaka H Hayashi T Tsuji S Clinical features of familial diffuse Lewy body disease Eur Neurol. 1997 38 Suppl 1 34 38 10.1159/000113459 9276199 · DOI
  81. [88]Johnson J Hague SM Hanson M Gibson A Wilson KE Evans EW SNCA multiplication is not a common cause of Parkinson disease or dementia with Lewy bodies Neurology. 2004 63 3 554 556 10.1212/01.WNL.0000133401.09043.44 15304594 · DOI
  82. [89]Geiger JT Ding J Crain B Pletnikova O Letson C Dawson TM Next-generation sequencing reveals substantial genetic contribution to dementia with Lewy bodies Neurobiol Dis. 2016 94 55 62 10.1016/j.nbd.2016.06.004 27312774 PMC4983488 · DOI
  83. [90]Tsuang DW Dalan AM Eugenio CJ Poorkaj P Limprasert P La Spada AR Familial dementia with lewy bodies: a clinical and neuropathological study of 2 families Arch Neurol. 2002 59 10 1622 1630 10.1001/archneur.59.10.1622 12374501 · DOI
  84. [91]Bonner LT Tsuang DW Cherrier MM Eugenio CJ Du Jennifer Q Steinbart EJ Familial dementia with Lewy bodies with an atypical clinical presentation J Geriatr Psychiatry Neurol. 2003 16 1 59 64 10.1177/0891988702250585 12641375 PMC1482838 · DOI
  85. [92]Ohtake H Limprasert P Fan Y Onodera O Kakita A Takahashi H Beta-synuclein gene alterations in dementia with Lewy bodies Neurology. 2004 63 5 805 811 10.1212/01.WNL.0000139870.14385.3C 15365127 PMC1808539 · DOI
  86. [93]Fujioka S Sundal C Strongosky AJ Castanedes MC Rademakers R Ross OA Sequence variants in eukaryotic translation initiation factor 4-gamma (eIF4G1) are associated with Lewy body dementia Acta neuropathologica. 2013 125 3 425 438 10.1007/s00401-012-1059-4 23124435 PMC3580022 · DOI
  87. [94]Chartier-Harlin MC Dachsel JC Vilarino-Guell C Lincoln SJ Lepretre F Hulihan MM Translation initiator EIF4G1 mutations in familial Parkinson disease Am J Hum Genet. 2011 89 3 398 406 10.1016/j.ajhg.2011.08.009 21907011 PMC3169825 · DOI
  88. [95]Brett FM Henson C Staunton H Familial diffuse Lewy body disease, eye movement abnormalities, and distribution of pathology Arch Neurol. 2002 59 3 464 467 10.1001/archneur.59.3.464 11890854 · DOI
  89. [96]SantaCruz KS Walker Z Swagerty D Piggott MA Ryo-Yang M McKeith IG Clinical presentations in monozygotic twins with dementia with Lewy bodies J Am Med Dir Assoc. 2002 3 3 175 179 10.1016/S1525-8610(04)70461-2 12807662 · DOI
  90. [97]Keogh MJ Kurzawa-Akanbi M Griffin H Douroudis K Ayers KL Hussein RI Exome sequencing in dementia with Lewy bodies Transl Psychiatry. 2016 6 e728 10.1038/tp.2015.220 26836416 PMC4872424 · DOI
  91. [98]Bras J Guerreiro R Darwent L Parkkinen L Ansorge O Escott-Price V Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies Hum Mol Genet. 2014 23 23 6139 6146 10.1093/hmg/ddu334 24973356 PMC4222357 · DOI · Paper page
  92. [99]Guerreiro R Ross OA Kun-Rodrigues C Hernandez DG Orme T Eicher JD Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study Lancet neurology. 2018 17 1 64 74 10.1016/S1474-4422(17)30400-3 29263008 PMC5805394 · DOI · Paper page
  93. [100]Orme T Guerreiro R Bras J The Genetics of Dementia with Lewy Bodies: Current Understanding and Future Directions Curr Neurol Neurosci Rep. 2018 18 10 67 10.1007/s11910-018-0874-y 30097731 PMC6097049 · DOI
  94. [101]Vergouw LJM van Steenoven I van de Berg WDJ Teunissen CE van Swieten JC Bonifati V An update on the genetics of dementia with Lewy bodies Parkinsonism Relat Disord. 2017 43 1 8 10.1016/j.parkreldis.2017.07.009 28734699 · DOI
  95. [102]Leverenz JB Fishel MA Peskind ER Montine TJ Nochlin D Steinbart E Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype Arch Neurol. 2006 63 3 370 376 10.1001/archneur.63.3.370 16533963 PMC1892620 · DOI · Paper page
  96. [103]Tsuang D Leverenz JB Lopez OL Hamilton RL Bennett DA Schneider JA APOE epsilon4 increases risk for dementia in pure synucleinopathies JAMA Neurol. 2013 70 2 223 228 10.1001/jamaneurol.2013.600 23407718 PMC3580799 · DOI · Paper page
  97. [104]Dickson DW Heckman MG Murray ME Soto AI Walton RL Diehl NN APOE epsilon4 is associated with severity of Lewy body pathology independent of Alzheimer pathology Neurology. 2018 91 12 e1182 e1e95 10.1212/WNL.0000000000006212 30143564 PMC6161556 · DOI · Paper page
  98. [105]Singleton AB Wharton A O'Brien KK Walker MP McKeith IG Ballard CG Clinical and neuropathological correlates of apolipoprotein E genotype in dementia with Lewy bodies Dement Geriatr Cogn Disord. 2002 14 4 167 175 10.1159/000066022 12411758 · DOI
  99. [106]Moskvina V Harold D Russo G Vedernikov A Sharma M Saad M Analysis of genome-wide association studies of Alzheimer disease and of Parkinson disease to determine if these 2 diseases share a common genetic risk JAMA Neurol. 2013 70 10 1268 1276 23921447 PMC5978422
  100. [107]Nalls MA Duran R Lopez G Kurzawa-Akanbi M McKeith IG Chinnery PF A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies JAMA Neurol. 2013 70 6 727 735 10.1001/jamaneurol.2013.1925 23588557 PMC3841974 · DOI
  101. [108]Sidransky E Nalls MA Aasly JO Aharon-Peretz J Annesi G Barbosa ER Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease The New England journal of medicine. 2009 361 17 1651 1661 10.1056/NEJMoa0901281 19846850 PMC2856322 · DOI · Paper page
  102. [109]Burton EJ Karas G Paling SM Barber R Williams ED Ballard CG Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry NeuroImage. 2002 17 2 618 630 10.1006/nimg.2002.1197 12377138 · DOI
  103. [110]Burton EJ Barber R Mukaetova-Ladinska EB Robson J Perry RH Jaros E Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis Brain: a journal of neurology. 2009 132 Pt 1 195 203 10.1093/brain/awn298 19022858 · DOI
  104. [111]Serpell LC Berriman J Jakes R Goedert M Crowther RA Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation Proceedings of the National Academy of Sciences of the United States of America. 2000 97 9 4897 4902 10.1073/pnas.97.9.4897 10781096 PMC18329 · DOI
  105. [112]Goedert M Spillantini MG Del Tredici K Braak H 100 years of Lewy pathology Nature reviews Neurology. 2013 9 1 13 24 10.1038/nrneurol.2012.242 23183883 · DOI · Paper page
  106. [113]Spillantini MG Crowther RA Jakes R Hasegawa M Goedert M alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies Proceedings of the National Academy of Sciences of the United States of America. 1998 95 11 6469 6473 10.1073/pnas.95.11.6469 9600990 PMC27806 · DOI
  107. [114]Fujiwara H Hasegawa M Dohmae N Kawashima A Masliah E Goldberg MS alpha-Synuclein is phosphorylated in synucleinopathy lesions Nature cell biology. 2002 4 2 160 164 10.1038/ncb748 11813001 · DOI
  108. [115]Giasson BI Duda JE Murray IV Chen Q Souza JM Hurtig HI Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions Science. 2000 290 5493 985 989 10.1126/science.290.5493.985 11062131 · DOI
  109. [116]Rott R Szargel R Shani V Hamza H Savyon M Abd Elghani F SUMOylation and ubiquitination reciprocally regulate alpha-synuclein degradation and pathological aggregation Proceedings of the National Academy of Sciences of the United States of America. 2017 114 50 13176 13181 10.1073/pnas.1704351114 29180403 PMC5740625 · DOI
  110. [117]Saito Y Kawashima A Ruberu NN Fujiwara H Koyama S Sawabe M Accumulation of phosphorylated alpha-synuclein in aging human brain Journal of neuropathology and experimental neurology. 2003 62 6 644 654 10.1093/jnen/62.6.644 12834109 · DOI
  111. [118]Obi K Akiyama H Kondo H Shimomura Y Hasegawa M Iwatsubo T Relationship of phosphorylated alpha-synuclein and tau accumulation to Abeta deposition in the cerebral cortex of dementia with Lewy bodies Experimental neurology. 2008 210 2 409 420 10.1016/j.expneurol.2007.11.019 18164295 · DOI
  112. [119]Jellinger KA Attems J Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies? Acta neuropathologica. 2006 112 3 253 260 10.1007/s00401-006-0088-2 16804711 · DOI
  113. [120]Edison P Rowe CC Rinne JO Ng S Ahmed I Kemppainen N Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography Journal of neurology, neurosurgery, and psychiatry. 2008 79 12 1331 1338 10.1136/jnnp.2007.127878 18653550 · DOI
  114. [121]Tsuboi Y Dickson DW Dementia with Lewy bodies and Parkinson's disease with dementia: are they different? Parkinsonism Relat Disord. 2005 11 Suppl 1 S47 S51 10.1016/j.parkreldis.2004.10.014 15885629 · DOI
  115. [122]Kovacs GG Alafuzoff I Al-Sarraj S Arzberger T Bogdanovic N Capellari S Mixed brain pathologies in dementia: the BrainNet Europe consortium experience Dement Geriatr Cogn Disord. 2008 26 4 343 350 10.1159/000161560 18849605 · DOI · Paper page
  116. [123]Kovacs GG Milenkovic I Wohrer A Hoftberger R Gelpi E Haberler C Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series Acta neuropathologica. 2013 126 3 365 384 10.1007/s00401-013-1157-y 23900711 · DOI
  117. [124]Jellinger KA Attems J Neuropathological evaluation of mixed dementia Journal of the neurological sciences. 2007 257 1-2 80 87 10.1016/j.jns.2007.01.045 17324442 · DOI
  118. [125]Dugger BN, Adler CH, Shill HA, Caviness J, Jacobson S, Driver-Dunckley E, et al. Concomitant pathologies among a spectrum of parkinsonian disorders. Parkinsonism Relat Disord. 2014. PMC4028418 24637124
  119. [127]McAleese KE Walker L Erskine D Thomas AJ McKeith IG Attems J TDP-43 pathology in Alzheimer's disease, dementia with Lewy bodies and ageing Brain pathology (Zurich, Switzerland) 2017 27 4 472 479 10.1111/bpa.12424 PMC8029292 27495267 · DOI
  120. [128]Irwin DJ Grossman M Weintraub D Hurtig HI Duda JE Xie SX Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis Lancet neurology. 2017 16 1 55 65 10.1016/S1474-4422(16)30291-5 27979356 PMC5181646 · DOI
  121. [129]Howlett DR Whitfield D Johnson M Attems J O'Brien JT Aarsland D Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias Brain pathology (Zurich, Switzerland) 2015 25 4 401 408 10.1111/bpa.12182 PMC8029273 25103200 · DOI
  122. [130]Arai T Mackenzie IR Hasegawa M Nonoka T Niizato K Tsuchiya K Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies Acta neuropathologica. 2009 117 2 125 136 10.1007/s00401-008-0480-1 19139911 · DOI · Paper page
  123. [131]Nakashima-Yasuda H Uryu K Robinson J Xie SX Hurtig H Duda JE Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases Acta neuropathologica. 2007 114 3 221 229 10.1007/s00401-007-0261-2 17653732 · DOI · Paper page
  124. [132]Josephs KA Murray ME Whitwell JL Parisi JE Petrucelli L Jack CR Staging TDP-43 pathology in Alzheimer's disease Acta neuropathologica. 2014 127 3 441 450 10.1007/s00401-013-1211-9 24240737 PMC3944799 · DOI · Paper page
  125. [133]Josephs KA Whitwell JL Knopman DS Hu WT Stroh DA Baker M Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype Neurology. 2008 70 19 Pt 2 1850 1857 10.1212/01.wnl.0000304041.09418.b1 18401022 PMC2779031 · DOI
  126. [134]Josephs KA Whitwell JL Weigand SD Murray ME Tosakulwong N Liesinger AM TDP-43 is a key player in the clinical features associated with Alzheimer's disease Acta neuropathologica. 2014 127 6 811 824 10.1007/s00401-014-1269-z 24659241 PMC4172544 · DOI · Paper page
  127. [135]Miners S, Moulding H, de Silva R, Love S. Reduced vascular endothelial growth factor and capillary density in the occipital cortex in dementia with Lewy bodies. Brain pathology (Zurich, Switzerland). 2014, 24(4):334–43. PMC8029164 24521289
  128. [136]Serby M Brickman AM Haroutunian V Purohit DP Marin D Lantz M Cognitive burden and excess Lewy-body pathology in the Lewy-body variant of Alzheimer disease The American journal of geriatric psychiatry: official journal of the American Association for Geriatric Psychiatry. 2003 11 3 371 374 10.1097/00019442-200305000-00016 12724118 · DOI
  129. [137]Walker L McAleese KE Thomas AJ Johnson M Martin-Ruiz C Parker C Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes Acta neuropathologica. 2015 129 5 729 748 10.1007/s00401-015-1406-3 25758940 · DOI
  130. [138]Merdes AR Hansen LA Jeste DV Galasko D Hofstetter CR Ho GJ Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies Neurology. 2003 60 10 1586 1590 10.1212/01.WNL.0000065889.42856.F2 12771246 · DOI
  131. [139]Braak H Del Tredici K Rub U de Vos RA Jansen Steur EN Braak E Staging of brain pathology related to sporadic Parkinson's disease Neurobiology of aging. 2003 24 2 197 211 10.1016/S0197-4580(02)00065-9 12498954 · DOI · Paper page
  132. [140]Leverenz JB Hamilton R Tsuang DW Schantz A Vavrek D Larson EB Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient Brain pathology (Zurich, Switzerland) 2008 18 2 220 224 10.1111/j.1750-3639.2007.00117.x PMC2689097 18241240 · DOI
  133. [141]Braak H de Vos RA Bohl J Del Tredici K Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology Neuroscience letters. 2006 396 1 67 72 10.1016/j.neulet.2005.11.012 16330147 · DOI · Paper page
  134. [142]Wakabayashi K Takahashi H Takeda S Ohama E Ikuta F Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses Acta neuropathologica. 1988 76 3 217 221 10.1007/BF00687767 2850698 · DOI · Paper page
  135. [143]Beach TG Adler CH Sue LI Vedders L Lue L White Iii CL Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders Acta neuropathologica. 2010 119 6 689 702 10.1007/s00401-010-0664-3 20306269 PMC2866090 · DOI · Paper page
  136. [144]Beach TG Adler CH Serrano G Sue LI Walker DG Dugger BN Prevalence of Submandibular Gland Synucleinopathy in Parkinson's Disease, Dementia with Lewy Bodies and other Lewy Body Disorders Journal of Parkinson's disease. 2016 6 1 153 163 10.3233/JPD-150680 26756744 PMC5498170 · DOI
  137. [146]Brundin P Li JY Holton JL Lindvall O Revesz T Research in motion: the enigma of Parkinson's disease pathology spread Nature reviews Neuroscience. 2008 9 10 741 745 10.1038/nrn2477 18769444 · DOI
  138. [147]Clinton LK Blurton-Jones M Myczek K Trojanowski JQ LaFerla FM Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline The Journal of neuroscience: the official journal of the Society for Neuroscience. 2010 30 21 7281 7289 10.1523/JNEUROSCI.0490-10.2010 20505094 PMC3308018 · DOI · Paper page
  139. [149]Swirski M Miners JS de Silva R Lashley T Ling H Holton J Evaluating the relationship between amyloid-beta and alpha-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson's disease Alzheimer's research & therapy. 2014 6 5-8 77 10.1186/s13195-014-0077-y PMC4248436 25452767 · DOI
  140. [151]Lee VM Giasson BI Trojanowski JQ More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases Trends in neurosciences. 2004 27 3 129 134 10.1016/j.tins.2004.01.007 15036877 · DOI
  141. [152]Colom-Cadena M Gelpi E Charif S Belbin O Blesa R Marti MJ Confluence of alpha-synuclein, tau, and beta-amyloid pathologies in dementia with Lewy bodies Journal of neuropathology and experimental neurology. 2013 72 12 1203 12 10.1097/NEN.0000000000000018 24226269 · DOI
  142. [153]Gomez-Isla T Growdon WB McNamara M Newell K Gomez-Tortosa E Hedley-Whyte ET Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies Neurology. 1999 53 9 2003 2009 10.1212/WNL.53.9.2003 10599772 · DOI
  143. [154]Gomez-Tortosa E Newell K Irizarry MC Albert M Growdon JH Hyman BT Clinical and quantitative pathologic correlates of dementia with Lewy bodies Neurology. 1999 53 6 1284 1291 10.1212/WNL.53.6.1284 10522886 · DOI
  144. [155]Mattila PM Rinne JO Helenius H Dickson DW Roytta M Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease Acta neuropathologica. 2000 100 3 285 290 10.1007/s004019900168 10965798 · DOI
  145. [156]Weisman D Cho M Taylor C Adame A Thal LJ Hansen LA In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution Neurology. 2007 69 4 356 359 10.1212/01.wnl.0000266626.64913.0f 17646627 · DOI
  146. [157]Bodner RA Outeiro TF Altmann S Maxwell MM Cho SH Hyman BT Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases Proceedings of the National Academy of Sciences of the United States of America. 2006 103 11 4246 4251 10.1073/pnas.0511256103 16537516 PMC1449678 · DOI
  147. [158]Tanaka M Kim YM Lee G Junn E Iwatsubo T Mouradian MM Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective The Journal of biological chemistry. 2004 279 6 4625 4631 10.1074/jbc.M310994200 14627698 · DOI
  148. [159]Morris AM Watzky MA Agar JN Finke RG Fitting neurological protein aggregation kinetic data via a 2-step, minimal/"Ockham's razor" model: the Finke-Watzky mechanism of nucleation followed by autocatalytic surface growth Biochemistry. 2008 47 8 2413 2427 10.1021/bi701899y 18247636 · DOI
  149. [160]Fink AL The aggregation and fibrillation of alpha-synuclein Accounts of chemical research. 2006 39 9 628 634 10.1021/ar050073t 16981679 · DOI
  150. [161]Kuret J Chirita CN Congdon EE Kannanayakal T Li G Necula M Pathways of tau fibrillization Biochimica et biophysica acta. 2005 1739 2-3 167 178 10.1016/j.bbadis.2004.06.016 15615636 · DOI
  151. [162]Serpell LC Alzheimer's amyloid fibrils: structure and assembly Biochimica et biophysica acta. 2000 1502 1 16 30 10.1016/S0925-4439(00)00029-6 10899428 · DOI
  152. [163]Iljina M Garcia GA Horrocks MH Tosatto L Choi ML Ganzinger KA Kinetic model of the aggregation of alpha-synuclein provides insights into prion-like spreading Proceedings of the National Academy of Sciences of the United States of America. 2016 113 9 E1206 E1215 10.1073/pnas.1524128113 26884195 PMC4780632 · DOI
  153. [164]Conway KA Lee SJ Rochet JC Ding TT Harper JD Williamson RE Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants Annals of the New York Academy of Sciences. 2000 920 42 45 10.1111/j.1749-6632.2000.tb06903.x 11193175 · DOI
  154. [165]Lashuel HA Petre BM Wall J Simon M Nowak RJ Walz T Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils Journal of molecular biology. 2002 322 5 1089 1102 10.1016/S0022-2836(02)00735-0 12367530 · DOI
  155. [166]Fredenburg RA Rospigliosi C Meray RK Kessler JC Lashuel HA Eliezer D The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states Biochemistry. 2007 46 24 7107 7118 10.1021/bi7000246 17530780 · DOI
  156. [167]Lazaro DF Rodrigues EF Langohr R Shahpasandzadeh H Ribeiro T Guerreiro P Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation PLoS genetics. 2014 10 11 e1004741 10.1371/journal.pgen.1004741 25393002 PMC4230739 · DOI
  157. [168]de Oliveira RM Vicente Miranda H Francelle L Pinho R Szego EM Martinho R The mechanism of sirtuin 2-mediated exacerbation of alpha-synuclein toxicity in models of Parkinson disease PLoS biology. 2017 15 3 e2000374 10.1371/journal.pbio.2000374 28257421 PMC5336201 · DOI
  158. [169]Vicente Miranda H Szego EM Oliveira LMA Breda C Darendelioglu E de Oliveira RM Glycation potentiates alpha-synuclein-associated neurodegeneration in synucleinopathies Brain: a journal of neurology. 2017 140 5 1399 1419 10.1093/brain/awx056 28398476 · DOI
  159. [170]Yamin G Uversky VN Fink AL Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers FEBS letters. 2003 542 1-3 147 152 10.1016/S0014-5793(03)00367-3 12729915 · DOI
  160. [171]Uversky VN Yamin G Souillac PO Goers J Glaser CB Fink AL Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro FEBS letters. 2002 517 1-3 239 244 10.1016/S0014-5793(02)02638-8 12062445 · DOI
  161. [172]Paleologou KE Schmid AW Rospigliosi CC Kim HY Lamberto GR Fredenburg RA Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein The Journal of biological chemistry. 2008 283 24 16895 16905 10.1074/jbc.M800747200 18343814 PMC2423264 · DOI
  162. [173]Ma MR Hu ZW Zhao YF Chen YX Li YM Phosphorylation induces distinct alpha-synuclein strain formation Scientific reports. 2016 6 37130 10.1038/srep37130 27853185 PMC5112567 · DOI
  163. [174]Li W West N Colla E Pletnikova O Troncoso JC Marsh L Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations Proceedings of the National Academy of Sciences of the United States of America. 2005 102 6 2162 2167 10.1073/pnas.0406976102 15684072 PMC548541 · DOI
  164. [175]Buell AK Galvagnion C Gaspar R Sparr E Vendruscolo M Knowles TP Solution conditions determine the relative importance of nucleation and growth processes in alpha-synuclein aggregation Proceedings of the National Academy of Sciences of the United States of America. 2014 111 21 7671 7676 10.1073/pnas.1315346111 24817693 PMC4040554 · DOI
  165. [176]Gaspar R Meisl G Buell AK Young L Kaminski CF Knowles TPJ Secondary nucleation of monomers on fibril surface dominates alpha-synuclein aggregation and provides autocatalytic amyloid amplification Quarterly reviews of biophysics. 2017 50 e6 10.1017/S0033583516000172 29233218 · DOI
  166. [177]Kordower JH Chu Y Hauser RA Freeman TB Olanow CW Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease Nature medicine. 2008 14 5 504 506 10.1038/nm1747 18391962 · DOI · Paper page
  167. [178]Desplats P Lee HJ Bae EJ Patrick C Rockenstein E Crews L Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein Proceedings of the National Academy of Sciences of the United States of America. 2009 106 31 13010 13015 10.1073/pnas.0903691106 19651612 PMC2722313 · DOI · Paper page
  168. [179]Surmeier DJ Obeso JA Halliday GM Selective neuronal vulnerability in Parkinson disease Nature reviews Neuroscience. 2017 18 2 101 113 10.1038/nrn.2016.178 28104909 PMC5564322 · DOI
  169. [180]Mao X, Ou MT, Karuppagounder SS, Kam TI, Yin X, Xiong Y, et al. Pathological alpha-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science. 2016;353(6307). PMC5510615 27708076
  170. [181]Ferreira DG Temido-Ferreira M Vicente Miranda H Batalha VL Coelho JE Szego EM alpha-synuclein interacts with PrP(C) to induce cognitive impairment through mGluR5 and NMDAR2B Nature neuroscience. 2017 20 11 1569 1579 10.1038/nn.4648 28945221 · DOI
  171. [182]Erskine D Patterson L Alexandris A Hanson PS McKeith IG Attems J Regional levels of physiological alpha-synuclein are directly associated with Lewy body pathology Acta neuropathologica. 2018 135 1 153 154 10.1007/s00401-017-1787-6 29134319 · DOI
  172. [183]Luna E Decker SC Riddle DM Caputo A Zhang B Cole T Differential alpha-synuclein expression contributes to selective vulnerability of hippocampal neuron subpopulations to fibril-induced toxicity Acta neuropathologica. 2018 135 6 855 875 10.1007/s00401-018-1829-8 29502200 PMC5955788 · DOI
  173. [184]Pinotsi D Michel CH Buell AK Laine RF Mahou P Dobson CM Nanoscopic insights into seeding mechanisms and toxicity of alpha-synuclein species in neurons Proceedings of the National Academy of Sciences of the United States of America. 2016 113 14 3815 3819 10.1073/pnas.1516546113 26993805 PMC4833232 · DOI
  174. [185]Hurtig HI Trojanowski JQ Galvin J Ewbank D Schmidt ML Lee VM Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease Neurology. 2000 54 10 1916 1921 10.1212/WNL.54.10.1916 10822429 · DOI
  175. [186]Harding AJ Halliday GM Cortical Lewy body pathology in the diagnosis of dementia Acta neuropathologica. 2001 102 4 355 363 11603811
  176. [187]Ballard CG Jacoby R Del Ser T Khan MN Munoz DG Holmes C Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with lewy bodies The American journal of psychiatry. 2004 161 5 843 849 10.1176/appi.ajp.161.5.843 15121649 · DOI
  177. [188]Kramer ML Schulz-Schaeffer WJ Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies The Journal of neuroscience: the official journal of the Society for Neuroscience. 2007 27 6 1405 1410 10.1523/JNEUROSCI.4564-06.2007 17287515 PMC6673583 · DOI · Paper page
  178. [189]Bergeron C Petrunka C Weyer L Pollanen MS Altered neurofilament expression does not contribute to Lewy body formation The American journal of pathology. 1996 148 1 267 272 8546215 PMC1861588
  179. [190]Katsuse O Iseki E Marui W Kosaka K Developmental stages of cortical Lewy bodies and their relation to axonal transport blockage in brains of patients with dementia with Lewy bodies Journal of the neurological sciences. 2003 211 1-2 29 35 10.1016/S0022-510X(03)00037-6 12767494 · DOI
  180. [191]Tompkins MM Hill WD Contribution of somal Lewy bodies to neuronal death Brain research. 1997 775 1-2 24 29 10.1016/S0006-8993(97)00874-3 9439824 · DOI
  181. [193]Parkkinen L O'Sullivan SS Collins C Petrie A Holton JL Revesz T Disentangling the relationship between lewy bodies and nigral neuronal loss in Parkinson's disease Journal of Parkinson's disease. 2011 1 3 277 286 23939308 PMC4196643
  182. [194]Pountney DL Voelcker NH Gai WP Annular alpha-synuclein oligomers are potentially toxic agents in alpha-synucleinopathy Hypothesis. Neurotoxicity research. 2005 7 1-2 59 67 10.1007/BF03033776 15639798 · DOI
  183. [195]Giehm L Svergun DI Otzen DE Vestergaard B Low-resolution structure of a vesicle disrupting &alpha;-synuclein oligomer that accumulates during fibrillation Proceedings of the National Academy of Sciences of the United States of America. 2011 108 8 3246 3251 10.1073/pnas.1013225108 21300904 PMC3044375 · DOI
  184. [197]Pacheco C Aguayo LG Opazo C An extracellular mechanism that can explain the neurotoxic effects of alpha-synuclein aggregates in the brain Frontiers in physiology. 2012 3 297 10.3389/fphys.2012.00297 22934048 PMC3429068 · DOI
  185. [198]Pacheco CR Morales CN Ramirez AE Munoz FJ Gallegos SS Caviedes PA Extracellular alpha-synuclein alters synaptic transmission in brain neurons by perforating the neuronal plasma membrane Journal of neurochemistry. 2015 132 6 731 741 10.1111/jnc.13060 25669123 · DOI
  186. [199]Emmanouilidou E Stefanis L Vekrellis K Cell-produced alpha-synuclein oligomers are targeted to, and impair, the 26S proteasome Neurobiology of aging. 2010 31 6 953 968 10.1016/j.neurobiolaging.2008.07.008 18715677 · DOI
  187. [200]Ingelsson M Alpha-Synuclein Oligomers-Neurotoxic Molecules in Parkinson's Disease and Other Lewy Body Disorders Frontiers in neuroscience. 2016 10 408 10.3389/fnins.2016.00408 27656123 PMC5011129 · DOI
  188. [201]Bengoa-Vergniory N Roberts RF Wade-Martins R Alegre-Abarrategui J Alpha-synuclein oligomers: a new hope Acta neuropathologica. 2017 134 6 819 838 10.1007/s00401-017-1755-1 28803412 PMC5663814 · DOI
  189. [202]Paiva I Jain G Lazaro DF Jercic KG Hentrich T Kerimoglu C Alpha-synuclein deregulates the expression of COL4A2 and impairs ER-Golgi function Neurobiol Dis. 2018 119 121 135 10.1016/j.nbd.2018.08.001 30092270 · DOI
  190. [203]Li B Ge P Murray KA Sheth P Zhang M Nair G Cryo-EM of full-length alpha-synuclein reveals fibril polymorphs with a common structural kernel Nature communications. 2018 9 1 3609 10.1038/s41467-018-05971-2 30190461 PMC6127345 · DOI
  191. [204]Peng C Gathagan RJ Covell DJ Medellin C Stieber A Robinson JL Cellular milieu imparts distinct pathological alpha-synuclein strains in alpha-synucleinopathies Nature. 2018 557 7706 558 563 10.1038/s41586-018-0104-4 29743672 PMC5970994 · DOI · Paper page
  192. [205]Jung BC Lim YJ Bae EJ Lee JS Choi MS Lee MK Amplification of distinct alpha-synuclein fibril conformers through protein misfolding cyclic amplification Experimental & molecular medicine. 2017 49 4 e314 10.1038/emm.2017.1 28386127 PMC5420798 · DOI
  193. [206]Labbe C Heckman MG Lorenzo-Betancor O Soto-Ortolaza AI Walton RL Murray ME MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies Alzheimers Dement. 2016 12 12 1297 1304 10.1016/j.jalz.2016.05.002 27287057 PMC5143206 · DOI
  194. [207]Meeus B Verstraeten A Crosiers D Engelborghs S Van den Broeck M Mattheijssens M DLB and PDD: a role for mutations in dementia and Parkinson disease genes? Neurobiology of aging 2012 33 3 629 e5 629e18 10.1016/j.neurobiolaging.2011.10.014 22118943 · DOI
  195. [208]Labbe C Ogaki K Lorenzo-Betancor O Soto-Ortolaza AI Walton RL Rayaprolu S Role for the microtubule-associated protein tau variant p.A152T in risk of alpha-synucleinopathies Neurology. 2015 85 19 1680 1686 10.1212/WNL.0000000000001946 26333800 PMC4653108 · DOI
  196. [209]Heckman MG Soto-Ortolaza AI Contreras MYS Murray ME Pedraza O Diehl NN LRRK2 variation and dementia with Lewy bodies Parkinsonism Relat Disord. 2016 31 98 103 10.1016/j.parkreldis.2016.07.015 27521182 PMC5048558 · DOI
  197. [210]Piscopo P Marcon G Piras MR Crestini A Campeggi LM Deiana E A novel PSEN2 mutation associated with a peculiar phenotype Neurology. 2008 70 17 1549 1554 10.1212/01.wnl.0000310643.53587.87 18427071 · DOI
  198. [211]Keogh MJ Wei W Wilson I Coxhead J Ryan S Rollinson S Genetic compendium of 1511 human brains available through the UK Medical Research Council Brain Banks Network Resource Genome Res. 2017 27 1 165 173 10.1101/gr.210609.116 28003435 PMC5204341 · DOI
  199. [212]Guyant-Marechal I Berger E Laquerriere A Rovelet-Lecrux A Viennet G Frebourg T Intrafamilial diversity of phenotype associated with app duplication Neurology. 2008 71 23 1925 1926 10.1212/01.wnl.0000339400.64213.56 19047566 · DOI

Cited by

Sorted by citations

Authors
Outeiro, T. F., Koss, D. J., Erskine, D., Walker, L., Kurzawa-Akanbi, M., Burn, D., Donaghy, P., Morris, C., Taylor, J.-P., Thomas, A., Attems, J., & McKeith, I.
Affiliations
  • Universitätsmedizin Göttingen (DE)
  • Newcastle University (GB)
Corresponding author
  • Outeiro, Tiago Fleming
  • McKeith, Ian
ORCID
Venue
Molecular Neurodegeneration
Publisher
Springer Science and Business Media LLC
Published
2019-01-21
Volume
14
Issue
1
Pages
5-5
ISSN
1750-1326 (ISSN-L)
DOI
10.1186/s13024-019-0306-8
PMC
PMC6341685
OpenAlex
W2913102923
Cited by
381
References
12
Citations by year
2026: 21 · 2025: 61 · 2024: 80 · 2023: 53 · 2022: 57 · 2021: 57 · 2020: 32 · 2019: 19
FWCI
5.52
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Neurodegeneration (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Discovery Research Portal (University of Dundee) (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
  • MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
  • Newcastle University ePrints (Newcastle Univesity) (cc-by)
Funders
  • Alzheimer's Society
  • National Institute for Health and Care Research (NF-SI-0611-10048, CL-2016-01-007, ACF-2015-01-010)
  • Newcastle University (G0400074)
  • Deutsche Forschungsgemeinschaft
  • Newcastle upon Tyne Hospitals NHS Foundation Trust
  • National Institutes of Health
  • Medical Research Council (G0400074)
  • NIHR Newcastle Biomedical Research Centre
Topics
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
dementia with Lewy bodies, Lewy bodies, Lewy neurites, alpha-synuclein aggregation, synucleinopathies, Parkinson's disease dementia, differential diagnosis, clinical criteria, neurodegeneration, cognitive decline, treatment options
MeSH terms
Humans, Lewy Body Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review